US Patent

US9987262 — Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Method of Use · Assigned to Akebia Therapeutics Inc · Expires 2034-11-14 · 8y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects solid forms of the drug vadadustat and methods of using them to treat various diseases and/or disorders.

USPTO Abstract

Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.

Drugs covered by this patent

vadadustat (VADADUSTAT)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3876`	—	vadadustat
`U-3876`	—	vadadustat
`U-3876`	—	vadadustat

Patent Metadata

Patent number: US9987262
Jurisdiction: US
Classification: Method of Use
Expires: 2034-11-14
Drug substance claim: No
Drug product claim: No
Assignee: Akebia Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.